¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"hepatitis A virus"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • adeno-associated virus
    ¾Æµ¥³ë°ü·Ã¹ÙÀÌ·¯½º
  • Bayou virus
    ¹ÙÀ¯¹ÙÀÌ·¯½º
  • croup-associated virus
    Å©·çÇÁ°ü·Ã¹ÙÀÌ·¯½º
  • defective virus
    °á¼Õ¹ÙÀÌ·¯½º
  • Duvenhage virus
    µàº¥ÇìÀÌÁî¹ÙÀÌ·¯½º
  • dengue virus
    µ­±â¹ÙÀÌ·¯½º
  • DNA virus
    DNA¹ÙÀÌ·¯½º
  • enteric cytopathogenic human orphan virus
    ¿¡ÄÚ¹ÙÀÌ·¯½º
  • enveloped virus
    ²®Áúº¸À¯¹ÙÀÌ·¯½º, ¿ÜÇǺ¸À¯¹ÙÀÌ·¯½º
  • epidemic gastroenteritis virus
    À¯ÇàÀ§Àå¿°¹ÙÀÌ·¯½º
  • Epstein-Barr virus
    ¿¦½ºÅ¸ÀÎ-¹Ù¹ÙÀÌ·¯½º
  • foamy virus
    °ÅǰÇü¼º¹ÙÀÌ·¯½º
  • helper virus
    º¸Á¶¹ÙÀÌ·¯½º
  • hemadsorption virus
    Ç÷±¸ÈíÂø¹ÙÀÌ·¯½º
  • herpes simplex virus
    ´Ü¼øÇ츣Æä½º¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • chronic persistent hepatitis
    ¸¸¼ºÁö¼Ó°£¿°
  • delta hepatitis
    µðÇü°£¿°
  • drug-induced hepatitis
    ¾à¹°°£¿°
  • epidemic hepatitis
    À¯Ç༺°£¿°
  • fulminant hepatitis
    Àü°Ý°£¿°
  • granulomatous hepatitis
    À°¾ÆÁ¾°£¿°
  • gummatous hepatitis
    °í¹«Á¾°£¿°
  • hepatitis
    °£¿°
  • hepatitis A
    ¿¡ÀÌÇü°£¿°
  • hepatitis B
    ºñÇü°£¿°
  • hepatitis C
    ¾¾Çü°£¿°
  • hepatitis contagiosa canis
    °³Àü¿°°£¿°
  • hepatitis D
    µðÇü°£¿°
  • halothane hepatitis
    ÇÒ·Îź°£¿°
  • hepatitis carrier state
    °£¿°º¸±ÕÀÚ»óÅÂ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • hepatitis,chronic active
    ¸¸¼ºÈ°µ¿¼º(Ø·àõüÀÔÑàõ)
  • hepatitis,chronic persistent
    ¸¸¼ºÁö¼Ó¼º(Ø·àõò¥áÙàõ)
  • hepatitis,delta
    µ¨Å¸
  • hepatitis,fulminant
    Àü°Ý¼º
  • hepatitis,lupoid
    ³¶Ã¢¸ð¾ç
  • hepatitis,non-a, non-b
    non-A, non-B
  • hepatitis,type a
    A Çü
  • hepatitis,type b
    B Çü
  • infantile hepatitis
    ¿µ¾Æ°£¿°.
  • infectious hepatitis
    Àü¿°¼º °£¿°, AÇü°£¿°
  • infectious hepatitis
    Àü¿°¼º °£¿°(îîæøàõÊÜæú).
  • post transfusion hepatitis
    ¼öÇ÷Èİ£¿°.
  • posttransfusion hepatitis
    ¼öÇ÷Èİ£¿°.
  • Aedes iridescent virus
    ½£¸ð±â ¹«Áö°³ ¹ÙÀÌ·¯½º
  • African horse sickness virus
    ¾ÆÇÁ¸®Ä« ¸»º´¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • epizootic hepatitis
    µ¿¹°À¯Ç༺ °£¿°.
  • fulminant hepatitis
    Àü°Ý¼º °£¿°
  • fulminant hepatitis
    Àü°Ý¼º °£¿°.
  • fulminant hepatitis
    Àü°Ý¼º°£¿°(¡­ÊÜæú)
  • fulminating hepatitis
    Àü°Ý¼º °£¿°.
  • granulomatous hepatitis
    À°¾ÆÁ¾¼º °£¿°.
  • gummatous hepatitis
    °í¹«Á¾¼º °£¿°.
  • hemorrhagic hepatitis
    ÃâÇ÷(¼º) °£¿°.
  • hepatitis
    °£¿°(ÊÜæú).
  • hepatitis B core antigen (HBc Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen (HBs Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • hepatitis B surface antigen(HBs Ag)
    BÇü °£¿°Ç¥¸éÇ׿ø
  • hepatitis D coinfection
    D Çü °£¿°µ¿½Ã°¨¿°
  • hepatitis a
    AÇü°£¿°(¡­ÊÜæú)
  • hepatitis b
    BÇü°£¿°(¡­ÊÜæú)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HDV Hepatitis D(elta) Virus
  = HBV associated Delta Agent
HEV Hepatitis E Virus
DHBV duck hepatitis B virus
GHV goose hepatitis virus; growth hormone variant
HBsAG hepatitis B surface virus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HAV Hepatitis A Virus
HBV Hepatitis B virus
HBeAg Hepatitis B Virus e antigen
HBs Ag Hepatitis B Virus surface antigen
HBx Hepatitis B virus X protein
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • herpes virus
    Æ÷Áø ¹ÙÀÌ·¯½º, Ç츣Æä½º ¹ÙÀÌ·¯½º
    1. DNA ¹ÙÀÌ·¯½º Áß Å« ±×·ì¿¡ ¼ÓÇÏ¸ç ´ëºÎºÐÀÇ µ¿¹°¿¡¼­ ºÐ¸®µÈ´Ù. nucleoca
  • herpes zoster virus
    ¼öµÎ ´ë»ó Æ÷Áø ¹ÙÀÌ·¯½º, ´ë»ó Æ÷Áø ¹ÙÀÌ·¯½º
    1. °¨¿° ½Ã ³ú ½Å°æÀý, ô¼ö ÈıÙÀÇ ½Å°æÀý ¹× ¸»ÃʽŰæÀÇ ±Þ¼º ¿°Áõ¼º ÁúȯÀ» ¹ß»ý½ÃŰ¸ç ¸»ÃʽŰæ Áö¹è ¿µ¿ª¿¡ ÀÏÄ¡ÇÏ¿© ´ë»ó ¼öÆ÷¸¦ º¼ ¼ö ÀÖÀ¸¸ç µ¿ ºÎÀ§ÀÇ ½Å°æÅëÀ» ¾ß±âÇÑ´Ù. 2. ¾ËÆÄ Ç츣Æä½º ¹ÙÀÌ·¯½º·Î¼­ ÁÖ·Î Á¡¸·, ÇǺÎ, ½Å°æ µîÀ» ħ¹ü. ¹è½Å°æ±ÙÀýÀÇ ½Å°æ¿ø ÁÖÀ§ ¼¼Æ÷¿¡ Àáº¹ÇØ ÀÖ´Ù°¡ ¼ö³â ÈÄ ÀçȰ¼ºÈ­ÇÑ´Ù. ¼öµÎ¿Í ´ë»ó Æ÷ÁøÀ» ÀÏÀ¸Å²´Ù.
  • human immunodeficiency virus
    Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º
  • human immunodeficiency virus infection
    Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º °¨¿°
  • human papilloma virus
    ÀÎü À¯µÎÁ¾ ¹ÙÀÌ·¯½º
    ÀÎü Áúȯ°ú µ¿¹° Áúȯ°úÀÇ À¯»çÁ¡Àº ¸Å¿ì ³î¶ø´Ù. ÇǺÎÀÇ ÆíÆò »óÇÇ ¼¼Æ÷¿¡ ´ëÇÑ ÇöÀúÇÑ Ä£È­¼ºÀ» º¸ÀδÙ. µ¿¹°¿¡¼­ À¯µÎÁ¾ ¹ÙÀÌ·¯½º´Â ÆíÆò »óÇÇ¿¡ ¾ç¼º À¯µÎÁ¾, ÀåÀÇ ¼± »óÇÇ¿¡ ¼±Á¾, ¹æ±¤¿¡ À¯µÎÁ¾À» ÀÏÀ¸Å°¸ç »ó´çÇÑ ¼ö°¡ ¾Ç¼ºÀ¸·Î ÁøÇàµÈ´Ù. »ç¶÷¿¡¼­µµ ÈĵÎÀÇ À¯µÎÁ¾, ¿ÜÀ½, À½°æ, Ç×¹® ÁÖº¯ºÎ¿¡ ÷±Ô Äܵô·Ò
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human t-cell leukemia virus
    ÀÎü T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • Japanese encephalitis virus
    ÀϺ» ³ú¿° ¹ÙÀÌ·¯½º
    ÀϺ» ³ú¿°ÀÇ º´¿øÃ¼. 1934³â¿¡ ÇϾ߽ð¡ ³ú³» Á¢Á¾¹ý¿¡ ÀÇÇØ óÀ½ ¿ø¼þÀÌ¿¡°Ô ÀüÆÄÇϰí, 36³â¿¡´Â ´Ù´Ï±¸Ä¡, °¡»çÇ϶ó µîÀÌ ½ÇÇè¿ë Á㸦 ÀÌ¿ëÇÏ¿© ºÐ¸®¿¡ ¼º°øÇÏ¿´´Ù. Å©±â´Â 15¡­30 mÀÌ°í ¼¼ÀÎÆ®·çÀ̽º ³ú¿°À̳ª ¼­ ³ªÀÏ ³ú¿°ÀÇ ¹ÙÀÌ·¯½º¿Í ºñ½ÁÇѵ¥, º´µ¶ÀÇ ÁßÈ­ ½ÃÇèÀ¸·Î ±¸º°ÇÑ´Ù. ¸ð±â°¡ ¸Å°³ÇÏ¿© »ç¶÷°ú °¡Ãà¿¡ °¨¿°µÇ´Âµ¥, ¸ð±â°¡ ¾ø´Â µ¿°è¸¦ ¾î¶»°Ô ³Ñ±â°í ´ÙÀ½ÇØ¿¡ ´Ù½Ã À¯ÇàÇÏ´ÂÁö ÆÇ¸íµÇ¸é ¿¹¹æ ´ëÃ¥ÀÌ È®¸³µÇ´Â °ÍÀ̳ª ¾ÆÁ÷ ¹àÇôÁöÁö ¾Ê°í ÀÖ´Ù. ¿Â´ëÁö¹æ¿¡¼­´Â µ¿¸éÇÑ ¸ð±âÀÇ Ã¼³»¿¡¼­ ÇØ¸¦ ³Ñ±æ °¡´É¼ºµµ ÀÖÀ¸³ª ¾ÆÁ÷ ÀÔÁõµÇÁö ¾Ê¾Ò°í, ¸ð±â¸¦ Àâ¾Æ¸Ô´Â µµ¸¶¹ìÀ̳ª µµ¸¶¹ìºÙÀÌÀÇ Ã¼³»¿¡¼­ ÇØ¸¦ ³Ñ±æ °¡´É¼ºÀ̳ª, µÕÁö¸¦ ¶°³¯ ¼ö ¾ø´Â µé»õ, ƯÈ÷ ±îÄ¡·ùÀÇ Ã¼³»¿¡¼­ »ì¾Æ³²´Â´Ù´Â °ßÇØµµ ÀÖ´Ù. ÇÑÆí °¨¿°µÈ ¸»À̳ª µÅÁö´Â ±× ÇØÀÇ ¹ÙÀÌ·¯½º¸¦ ¼ºÀå½Ãų ¼ö´Â ÀÖÀ¸³ª ¹ÙÀÌ·¯½ºÀÇ º¸À¯ µ¿¹°Àº ¾Æ´Ï¶ó°í ÇÑ´Ù.
  • Lassa fever virus
    ¶ó»ç ¿­ ¹ÙÀÌ·¯½º
    ¾Æ·¹³ª ¹ÙÀÌ·¯½º°ú¿¡ ¼ÓÇÏ¸ç ¼­¾ÆÇÁ¸®Ä«¿¡ »ç´Â ¾ÆÇÁ¸®Ä« ÁýÁã »çÀÌ¿¡ Áö¼Ó °¨¿°µÇ°í ÀÖÀ¸¸ç »ç¶÷¿¡ ´ëÇÑ °¨¿°Àº Ÿ¾×À̳ª ´¢Áß¿¡ ¹è¼³µÈ ¹ÙÀÌ·¯½º¿¡ ¿À¿°µÈ À½½Ä¹°À̳ª ½Ä±â¸¦ ÅëÇØ¼­ ÀϾ´Ù.
  • lymphadenopathy virus
    ¸²ÇÁÀýÁõ ¹ÙÀÌ·¯½º
  • lymphocystis virus
    ÀÓÆÄ ³¶Á¾ ¹ÙÀÌ·¯½º
  • measles virus
    È«¿ª ¹ÙÀÌ·¯½º
    ÆÄ¶ó ¹Í¼Ò ¹ÙÀÌ·¯½ºÀÇ ÀϹÝÀû ¼º»óÀ» Áö´Ñ º´¿øÃ¼·Î, »ç¶÷°ú ¿ø¼þÀÌ¿¡ º´¿ø¼ºÀ» ³ªÅ¸³½´Ù. RNA ¹ÙÀÌ·¯½º·Î 56¡É¿¡¼­ 30ºÐ °¡¿­ÇÏ¸é ºÒȰ¼ºÈ­µÈ´Ù. È«¿ª ȯÀÚÀÇ Ä§, °¡·¡, ¿ÀÁÜ¿¡ ÀÖ´Ù. È«¿ª ¹ÙÀÌ·¯½º°¡ Á¸ÀçÇÏ¸é ¸²ÇÁ±¸ Áõ°¡¿Í ¹éÇ÷±¸ °¨¼Ò°¡ º¸ÀÌ°í ¸²ÇÁÀý, Æíµµ¼± µî¿¡´Â ´ÙÇÙ ¼¼Æ÷°¡ ³ªÅ¸³­´Ù
  • monkey pox virus
    ¿ø¼þÀÌ Æø½º ¹ÙÀÌ·¯½º
  • neonatal calf diarrhea corona virus
    ½Å»ý¾Æ ¼³»ç Äڷγª ¹ÙÀÌ·¯½º
  • neurotropic virus
    Çâ½Å°æ¼º ¹ÙÀÌ·¯½º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
chronic persisting hepatitis A form of chronic hepatitis that is usually benign, not progressing to cirrhosis, and usually asymptomatic without physical findings but with continuing abnormalities of tests of liver status.
Synonym: chronic persistent hepatitis.
(05 Mar 2000)
mouse hepatitis A form of hepatitis in mice due to synergism between the mouse hepatitis virus and Eperythrozoon coccoides.
Synonym: murine hepatitis.
(05 Mar 2000)
plasma cell hepatitis <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver.
Symptoms are those of chronic active hepatitis.
(27 Sep 1997)
MS-1 hepatitis A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom.
Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis.
(05 Mar 2000)
murine hepatitis A form of hepatitis in mice due to synergism between the mouse hepatitis virus and Eperythrozoon coccoides.
Synonym: murine hepatitis.
(05 Mar 2000)
halothane hepatitis Hepatocellular damage said to result from the administration of halothane anaesthesia.
(05 Mar 2000)
hepatitis <pathology> Inflammation of the liver.
(18 Nov 1997)
hepatitis A <virology> A form of viral hepatitis, known as infectious hepatitis, due to its ability to be spread through personal contact with oral secretions or stool. Virus will be shed in the stools of an infected individual 2-3 weeks prior to the onset of any symptoms. Hepatitis A may also be transmitted sexually. Symptoms are similar to those of influenza, but the skin and eyes may become yellow. Recent travel to a third world country is a risk factor. There is no specific treatment but infected individuals should avoid potentially hepatotoxic substances.
The virus is a small (27nm diameter) single stranded RNA virus with some resemblance to enteroviruses such as polio.
(27 Sep 1997)
hepatitis agents, gb Proposed members of the family flaviviridae. Gbv-b causes hepatitis in tamarins and possibly humans, and is the putative aetiological agent of a non-(a-e) hepatitis, gb hepatitis.
(12 Dec 1998)
hepatitis a immunization When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain healthcare workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
hepatitis, alcoholic An acute or chronic degenerative and inflammatory lesion of the liver in the alcoholic which is potentially progressive though sometimes reversible. It does not necessarily include steatosis, fibrosis, or cirrhosis of alcoholics, although it is frequently associated with these conditions. It is characterised by liver cell necrosis, infiltration by polymorphonuclear leukocytes and lymphocytes, and mallory bodies. The morphologic changes of chronic alcoholic hepatitis are not likely to be confused with chronic hepatitis (hepatitis, chronic).
(12 Dec 1998)
hepatitis antibodies Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis.
(12 Dec 1998)
hepatitis antigens Antigens from any of the hepatitis viruses including surface, core, and other associated antigens.
(12 Dec 1998)
hepatitis-associated antigen A term used for the surface antigen of hepatitis B virus before its nature was established.
See: hepatitis B surface antigen.
(05 Mar 2000)
hepatitis, autoimmune An unresolving, predominately periportal, hepatitis, usually with hypergammaglobulinaemia and serum autoantibodies. The existence of subgroups (types 1, 2, and 3) based on serological findings are controversial. Additionally, some patients have variant forms, where there are features associated with both autoimmune hepatitis and another type of chronic liver disease (overlap syndromes) or where there are findings incompatible with autoimmune hepatitis (outlier syndromes).
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á